LCZ696
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Conditions
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Trial Timeline
— → —
NCT ID
NCT02389933About LCZ696
LCZ696 is a pre-clinical stage product being developed by Novartis for Heart Failure With Reduced Ejection Fraction (HF-rEF). The current trial status is completed. This product is registered under clinical trial identifier NCT02389933. Target conditions include Heart Failure With Reduced Ejection Fraction (HF-rEF).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02389933 | Pre-clinical | Completed |
| NCT03909295 | Phase 3 | Terminated |
| NCT02661217 | Approved | Completed |
| NCT02226120 | Phase 3 | Completed |
| NCT01922089 | Phase 2 | Completed |
| NCT01621633 | Phase 2 | Completed |
| NCT01593787 | Phase 3 | Completed |
| NCT00913653 | Phase 2 | Completed |
| NCT01569815 | Phase 1 | Completed |
Competing Products
20 competing products in Heart Failure With Reduced Ejection Fraction (HF-rEF)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |